The world's first new drug for treating children's SLE has been unveiled at the Expo

At present, there are about 60,000 children with systemic lupus erythematosus (SLE) in China, compared with adult SLE, the standardized mortality rate of SLE in children is nearly 6 times that of adult SLE, and has the characteristics of more acute illness, more serious illness, more migration, kidney and nervous system more serious injury. At the 3rd China International Import Expo, held in Shanghai from November 5 to 10, the world's first and only biological agent for the treatment of children's SLE, Bellevue monoantin (Pyrideng), met the public.
Professor Xu Hong,
, head of the Department of Nephrology and Rheumatology at Fudan University's affiliated pediatric hospital, said: "Children's systemic lupus erythematosus can have a lot of adverse effects on children's growth, development, learning and psychology. At present, the treatment of systemic lupus in children mainly includes hormones and immunosuppressants, because children are in a critical period of growth and development, the long-term application of hormones and immunosuppressants can adversely affect their bone development, body image and growth potential. Therefore, clinically, there is an urgent need for new drugs with precise efficacy, high safety, small side effects and good prognosis for children. The future expansion of Bellevue mono-anti-adhesive disease will not only help doctors break the predicament of SLE treatment in existing children, but also help children reduce the risk of recurrence, achieve long-term, effective disease control, and protect their better growth.
study found that children with kidney damage were more common and severe than adults, with an incidence of 40% to 90% and 90% in the first year of development, so children with lupus were more dependent on hormones and used in doses. Because children are in a critical period of growth and development, the long-term application of hormones and immunosuppressants can adversely affect their bone development, body image and growth potential, such as short stature, osteoporosis, multi-factors affect the immune system of children.
Professor Sun Li, Director of Rheumatology Department, Fudan University Hospital, stressed: "Hormones are one of the main causes of delayed growth and development of lupus in children, the problem of too much hormone use in children is more serious than in adults, although children metabolize higher than adults, but large doses or even more than adult doses of hormones are being used in the long-term treatment of children with lupus." How to reduce the amount of hormones in children, reduce adverse hormonal reactions, while controlling disease activity, reducing and preventing organ damage is the difficulty in the treatment of lupus in children.
Bellevue monotherapy has been approved for treatment of SLE in children over 5 years of age in the United States, Europe and Japan, becoming the only biological agent approved for systemic lupus in children, and in China, Bellevue mono-paediatric adaptation has been included in the national priority review list and is expected to be approved in the near future, bringing new treatment options to children and families suffering from the disease.